Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amgen Inc (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record at $223 Billion; 2018 Sets Record $806 Billion

S&P Dow Jones Indices ("S&P DJI") announced today that preliminary Q4 2018 S&P 500® stock buybacks, or share repurchases, set a fourth consecutive record of $223.0 billion. This displaces the previous...

GOOGL : 1,197.38 (-0.85%)
AAPL : 188.74 (-1.21%)
AVGO : 292.16 (-0.17%)
CSCO : 52.73 (-0.02%)
C : 60.33 (-1.07%)
BAC : 26.84 (-0.63%)
JPM : 98.93 (-0.83%)
JNJ : 136.61 (-0.22%)
MRK : 82.35 (+0.07%)
ORCL : 52.74 (-0.06%)
AMGN : 186.59 (-0.06%)
PFE : 41.89 (+0.10%)
MSFT : 117.66 (+0.52%)
SBUX : 72.30 (+0.47%)
IBM : 139.18 (-0.19%)
WFC : 48.08 (-0.48%)
V : 153.03 (-0.03%)
SPGI : 205.01 (-0.23%)
FB : 166.29 (+1.19%)
HD : 189.68 (+0.49%)
WMT : 98.17 (-0.11%)
Spherix Global Insights' Quarterly Update on the US Migraine Prevention Market Reveals Best-In-Class Sales and Medical Affairs Support as the Driving Force Behind Teva's Ajovy Early Launch Success

With the 2018 launches of the new class of anti-calcitonin gene-related peptide (CGRP) therapies, specifically Amgen/Novartis' Aimovig, Teva's Ajovy, and Eli Lilly's Emgality, for the prevention of migraine,...

NVS : 93.31 (-0.12%)
AMGN : 186.59 (-0.06%)
Inovio Appoints Global Commercial Leader to its Board of Directors

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the appointment of Dr. Ann C. Miller to its Board of Directors. Dr. Miller had an outstanding marketing career launching and building blockbuster...

MRK : 82.35 (+0.07%)
INO : 3.62 (unch)
AMGN : 186.59 (-0.06%)
After Yesterday's Decline of 1.85%, Amgen Inc Offers Investors Better Value

Amgen Inc (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $187.84 to a high of $191.30. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $189.72...

AMGN : 186.59 (-0.06%)
Look for Shares of Amgen Inc to Potentially Rebound after Yesterday's 1.85% Sell Off

Amgen Inc (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $187.84 to a high of $191.30. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $189.72...

AMGN : 186.59 (-0.06%)
Imago BioSciences Announces $40 Million Series B Financing Led by Omega Funds

Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, today announced a $40 million Series B financing led by Omega Funds,...

AMGN : 186.59 (-0.06%)
Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis

Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the first planned interim analysis,...

CYTK : 8.84 (+1.03%)
AMGN : 186.59 (-0.06%)
Merchavia Expands Its Investments in Diagnostics: The Company to Invest NIS 1 Million in EFA - Engineering for All Ltd.

Merchavia Holdings and Investments (TASE: MRHL), an Israeli investment company specializing in early stage life sciences companies, announces that it is expanding its investments into the diagnostics sector....

AMGN : 186.59 (-0.06%)
Actinium Appoints Accomplished FDA and Industry Professional Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory Affairs

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today the appointment of Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory Affairs. In this role, Dr. Gokhale will...

ATNM : 0.47 (-6.00%)
AMGN : 186.59 (-0.06%)
Edison Issues Outlook on Nuevolution (NUEV)

LONDON, UK / ACCESSWIRE / March 19, 2019 / Positive progress in Nuevolution's (STO: NUEV) RORγt partnership with Almirall has triggered a EUR1m milestone payment (SEK10.5m) and we continue to forecast...

AMGN : 186.59 (-0.06%)
Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent

Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.

BAYRY : 16.1800 (-2.74%)
REGN : 395.00 (+0.82%)
AMGN : 186.59 (-0.06%)
SNY : 43.95 (-0.70%)
Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at ACC.19

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating...

CYTK : 8.84 (+1.03%)
AMGN : 186.59 (-0.06%)
Spectrum Pharma (SPPI) Withdraws Rolontis BLA, Shares Down

Spectrum Pharma (SPPI) withdraws the BLA seeking approval for Rolontis, as the FDA requests for additional manufacturing-related data.

SPPI : 9.80 (+2.40%)
AITB : 4.8900 (+2.95%)
INFI : 1.70 (-3.41%)
AMGN : 186.59 (-0.06%)
Corcept Therapeutics Appoints Former Amgen Development Executive, Andreas Grauer, M.D., as Chief Medical Officer

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

CORT : 11.01 (-1.43%)
AMGN : 186.59 (-0.06%)
Roche Gets Approval for Label Expansion of MabThera in Europe

Roche (RHHBY) gets EC approval for the label expansion of its legacy RA drug, MabThera for pemphigus vulgaris.

CELG : 87.92 (-0.26%)
NVS : 93.31 (-0.12%)
RHHBY : 33.8300 (+0.21%)
AMGN : 186.59 (-0.06%)
Amgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke

Amgen (NASDAQ:AMGN) today announced plans to conduct VESALIUS-CV, a multinational clinical outcomes study for Repatha® (evolocumab) which will involve at least 13,000 patients worldwide at high risk of...

AMGN : 186.59 (-0.06%)
Roche Receives EC Approval for Label Expansion of Hemlibra

Roche (RHHBY) gets approval from European Commission for a label expansion of hemophilia drug, Hemlibra.

NVS : 93.31 (-0.12%)
ABBV : 79.51 (-0.31%)
RHHBY : 33.8300 (+0.21%)
AMGN : 186.59 (-0.06%)
After Yesterday's Rally of 1.95% Shares Could Potentially Pullback

Amgen Inc (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $185.43 to a high of $187.92. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $184.62...

AMGN : 186.59 (-0.06%)
Industry Veteran Joins Vivacitas Oncology As New Biotech CEO

Pramod Gupta, PhD fills the shoes of past CEO Dr. Joseph Rubinfeld - a co-founder of Amgen, Supergen, and Vivacitas Oncology

AMGN : 186.59 (-0.06%)
Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval

FDA approves Pfizer's (PFE) biosimilar version Roche's (RHHBY) breast cancer drug, Herceptin.

ABBV : 79.51 (-0.31%)
RHHBY : 33.8300 (+0.21%)
AMGN : 186.59 (-0.06%)
PFE : 41.89 (+0.10%)

Van Meerten Stock Picks

Trilogy Metals - Pick of the Day
My Stock Pick of the Day belongs metal mining company Trilogy Metals(TMQ).
TMQ +0.11
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar